[go: up one dir, main page]

MX2018014081A - Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal. - Google Patents

Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.

Info

Publication number
MX2018014081A
MX2018014081A MX2018014081A MX2018014081A MX2018014081A MX 2018014081 A MX2018014081 A MX 2018014081A MX 2018014081 A MX2018014081 A MX 2018014081A MX 2018014081 A MX2018014081 A MX 2018014081A MX 2018014081 A MX2018014081 A MX 2018014081A
Authority
MX
Mexico
Prior art keywords
trigeminal neuralgia
carbamate compound
prevent
pharmaceutical composition
treat trigeminal
Prior art date
Application number
MX2018014081A
Other languages
English (en)
Other versions
MX389613B (es
Inventor
Ju Yi Han
Jae JO Min
Gwan Hwang Sun
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MX2018014081A publication Critical patent/MX2018014081A/es
Publication of MX389613B publication Critical patent/MX389613B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona a una composición farmacéutica para prevenir o tratar neuralgia trigeminal, la composición farmacéutica que comprende: un compuesto de carbamato de la fórmula química 1 o una sal, un solvato o un hidrato farmacéuticamente aceptable del mismo; y un portador farmacéuticamente aceptable. La composición farmacéutica, de acuerdo con la presente invención, puede permitir la prevención o tratamiento eficiente de la neuralgia trigeminal.
MX2018014081A 2016-05-19 2017-05-18 Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal. MX389613B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160061386 2016-05-19
PCT/KR2017/005172 WO2017200317A1 (ko) 2016-05-19 2017-05-18 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Publications (2)

Publication Number Publication Date
MX2018014081A true MX2018014081A (es) 2019-09-02
MX389613B MX389613B (es) 2025-03-20

Family

ID=60325324

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014081A MX389613B (es) 2016-05-19 2017-05-18 Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.

Country Status (14)

Country Link
US (2) US11207295B2 (es)
EP (1) EP3459542B1 (es)
JP (1) JP6960415B2 (es)
KR (1) KR102421013B1 (es)
CN (1) CN109310669B (es)
AU (1) AU2017267160B2 (es)
CA (1) CA3024284C (es)
DK (1) DK3459542T3 (es)
ES (1) ES2887338T3 (es)
MX (1) MX389613B (es)
PL (1) PL3459542T3 (es)
PT (1) PT3459542T (es)
RU (1) RU2751504C2 (es)
WO (1) WO2017200317A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3035674T3 (en) 2016-12-14 2025-09-08 Sk Biopharmaceuticals Co Ltd Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease
WO2020060251A1 (ko) * 2018-09-21 2020-03-26 에스케이바이오팜 주식회사 카바메이트 화합물 및 이를 포함하는 배합물의 급성 스트레스 장애 또는 외상 후 스트레스 장애의 예방, 경감 또는 치료를 위한 용도
EP3868375A4 (en) * 2018-10-19 2022-06-29 SK Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
DE2628420A1 (de) * 1976-06-24 1978-01-05 Bayer Ag 1-acyloxy-2-imidazolyl-1-phenyl- aethane, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide und nematizide
SK57899A3 (en) * 1996-12-31 2000-05-16 Guilford Pharm Inc N-linked ureas and carbamates of heterocyclic thioesters
WO2002067922A1 (en) * 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in the treatment of pain
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
JP4227121B2 (ja) 2005-06-08 2009-02-18 独立行政法人科学技術振興機構 神経因性疼痛治療剤
JP5683580B2 (ja) * 2009-06-22 2015-03-11 エスケー バイオファーマシューティカル カンパニー リミテッド カルバミン酸（ｒ）−１−アリール−２−テトラゾリル−エチルエステルの製造方法
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
WO2012062925A2 (en) * 2010-11-11 2012-05-18 Akron Molecules Gmbh Compounds and methods for treating pain
HUE035030T2 (en) 2014-05-09 2018-05-02 Tecnimede Sociedade Tecnico Medicinal S (R) -pirlindole and its pharmaceutically acceptable salts for use in medicine

Also Published As

Publication number Publication date
KR102421013B1 (ko) 2022-07-14
PL3459542T3 (pl) 2021-12-27
MX389613B (es) 2025-03-20
CA3024284A1 (en) 2017-11-23
US11207295B2 (en) 2021-12-28
JP6960415B2 (ja) 2021-11-05
EP3459542B1 (en) 2021-06-30
DK3459542T3 (da) 2021-09-13
RU2018144784A (ru) 2020-06-19
EP3459542A1 (en) 2019-03-27
CA3024284C (en) 2024-01-23
PT3459542T (pt) 2021-08-24
JP2019516722A (ja) 2019-06-20
AU2017267160B2 (en) 2022-11-10
CN109310669B (zh) 2022-02-22
WO2017200317A1 (ko) 2017-11-23
US20220087976A1 (en) 2022-03-24
AU2017267160A1 (en) 2018-12-13
RU2751504C2 (ru) 2021-07-14
KR20170131241A (ko) 2017-11-29
CN109310669A (zh) 2019-02-05
BR112018073556A2 (pt) 2019-03-19
EP3459542A4 (en) 2020-01-08
US20190175555A1 (en) 2019-06-13
RU2018144784A3 (es) 2020-08-11
ES2887338T3 (es) 2021-12-22

Similar Documents

Publication Publication Date Title
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
AR122783A2 (es) Inhibidores de kras g12c y métodos para su uso
MX2022000271A (es) Inhibidores de la quinasa progenitora hematopoyetica 1 y usos de los mismos.
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201991412A1 (ru) Ингибиторы поли(адф-рибоза)полимеразы (parp)
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
CO2020007162A2 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
MX2020003593A (es) Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
AR101740A1 (es) Terapia de combinación y composiciones
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
AR103680A1 (es) Inhibidores selectivos de bace1
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
CL2017001822A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
CO2019009000A2 (es) Combinaciones farmacéuticas para tratar cáncer
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MX2018014081A (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
MX2019004842A (es) Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc.
CL2019002025A1 (es) Derivados de pirrolotriazina como inhibidor de cinasas.